Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus gemcitabine/cisplatin as neoadjuvant therapy followed by adjuvant durvalumab in muscle-invasive bladder cancer
NL-OMON52537Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2019
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab, gemcitabine and cisplatin in bladder cancer and muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Pathologic complete response and Event-free survival. Started May 2019; status: active, not recruiting.
02
Drugs
durvalumabgemcitabinecisplatin
03
Conditions
bladder cancermuscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NL-OMON52537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52537.